| Breanna Hieb, CRNA | |
|
512 Skyline Blvd Ste 1, Cloquet, MN 55720-1199 | |
| (218) 879-4641 | |
| Not Available |
| Full Name | Breanna Hieb |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 5 Years |
| Location | 512 Skyline Blvd Ste 1, Cloquet, Minnesota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386204345 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | R-205865-2 (Minnesota) | Secondary |
| 367500000X | Nurse Anesthetist, Certified Registered | 2467 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Lukes Hospital | Duluth, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St Lukes Hospital Of Duluth | 7113834839 | 352 |
News Archive
ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it has entered into a research and license option agreement regarding its ICT-69 antibody with Roche Group (SWX: ROG.VX; RO.S, OTCQX: RHHBY), one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics.
Contrary to current policies recommending that non-invasive ventilation be avoided during an infectious outbreak, the author of a commentary (pre-embargo media link only http://www.cmaj.ca/embargo/cmaj081987.pdf) in CMAJ (Canadian Medical Association Journal) www.cmaj.ca argues that it should be used expeditiously in this setting.
Genzyme Corp., a diversified, global biotechnology company, today announced fourth-quarter and full year 2009 financial results and provided 2010 guidance that reflects growth across its businesses and a focus on strengthening core areas of the company.
Ophthalmic Imaging Systems, a leading digital imaging and informatics company, today announced that its revolutionary new portable imaging device, the OIS EyeScan, has received 510(k) market clearance from the U.S. Food and Drug Administration (FDA).
A powerful new biosensor developed by European researchers will help identify cells in the immune system that actively suppress tumour growth, then put them to use. Enlisting the patient's own immune system would be like sending reinforcements for resistance fighters.
› Verified 3 days ago
| Entity Name | St Lukes Hospital Of Duluth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902845068 PECOS PAC ID: 7113834839 Enrollment ID: O20031120000212 |
News Archive
ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it has entered into a research and license option agreement regarding its ICT-69 antibody with Roche Group (SWX: ROG.VX; RO.S, OTCQX: RHHBY), one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics.
Contrary to current policies recommending that non-invasive ventilation be avoided during an infectious outbreak, the author of a commentary (pre-embargo media link only http://www.cmaj.ca/embargo/cmaj081987.pdf) in CMAJ (Canadian Medical Association Journal) www.cmaj.ca argues that it should be used expeditiously in this setting.
Genzyme Corp., a diversified, global biotechnology company, today announced fourth-quarter and full year 2009 financial results and provided 2010 guidance that reflects growth across its businesses and a focus on strengthening core areas of the company.
Ophthalmic Imaging Systems, a leading digital imaging and informatics company, today announced that its revolutionary new portable imaging device, the OIS EyeScan, has received 510(k) market clearance from the U.S. Food and Drug Administration (FDA).
A powerful new biosensor developed by European researchers will help identify cells in the immune system that actively suppress tumour growth, then put them to use. Enlisting the patient's own immune system would be like sending reinforcements for resistance fighters.
› Verified 3 days ago
| Entity Name | Community Memorial Hospital Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003869082 PECOS PAC ID: 0042129991 Enrollment ID: O20040202001203 |
News Archive
ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it has entered into a research and license option agreement regarding its ICT-69 antibody with Roche Group (SWX: ROG.VX; RO.S, OTCQX: RHHBY), one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics.
Contrary to current policies recommending that non-invasive ventilation be avoided during an infectious outbreak, the author of a commentary (pre-embargo media link only http://www.cmaj.ca/embargo/cmaj081987.pdf) in CMAJ (Canadian Medical Association Journal) www.cmaj.ca argues that it should be used expeditiously in this setting.
Genzyme Corp., a diversified, global biotechnology company, today announced fourth-quarter and full year 2009 financial results and provided 2010 guidance that reflects growth across its businesses and a focus on strengthening core areas of the company.
Ophthalmic Imaging Systems, a leading digital imaging and informatics company, today announced that its revolutionary new portable imaging device, the OIS EyeScan, has received 510(k) market clearance from the U.S. Food and Drug Administration (FDA).
A powerful new biosensor developed by European researchers will help identify cells in the immune system that actively suppress tumour growth, then put them to use. Enlisting the patient's own immune system would be like sending reinforcements for resistance fighters.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Breanna Hieb, CRNA 512 Skyline Blvd Ste 1, Cloquet, MN 55720-1199 Ph: (218) 879-4641 | Breanna Hieb, CRNA 512 Skyline Blvd Ste 1, Cloquet, MN 55720-1199 Ph: (218) 879-4641 |
News Archive
ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it has entered into a research and license option agreement regarding its ICT-69 antibody with Roche Group (SWX: ROG.VX; RO.S, OTCQX: RHHBY), one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics.
Contrary to current policies recommending that non-invasive ventilation be avoided during an infectious outbreak, the author of a commentary (pre-embargo media link only http://www.cmaj.ca/embargo/cmaj081987.pdf) in CMAJ (Canadian Medical Association Journal) www.cmaj.ca argues that it should be used expeditiously in this setting.
Genzyme Corp., a diversified, global biotechnology company, today announced fourth-quarter and full year 2009 financial results and provided 2010 guidance that reflects growth across its businesses and a focus on strengthening core areas of the company.
Ophthalmic Imaging Systems, a leading digital imaging and informatics company, today announced that its revolutionary new portable imaging device, the OIS EyeScan, has received 510(k) market clearance from the U.S. Food and Drug Administration (FDA).
A powerful new biosensor developed by European researchers will help identify cells in the immune system that actively suppress tumour growth, then put them to use. Enlisting the patient's own immune system would be like sending reinforcements for resistance fighters.
› Verified 3 days ago
Mr. Patrick A Bailey, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 512 Skyline Blvd, Cloquet, MN 55720 Phone: 218-878-7699 | |
Joseph Vidmar, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 512 Skyline Blvd Ste 1, Cloquet, MN 55720 Phone: 218-879-4641 | |
Mr. Matthew J. Lewis, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 512 Skyline Blvd, Cloquet, MN 55720 Phone: 218-878-7699 |